Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

720 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of miRNA modulators to PARP inhibitor response.
Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A. Neijenhuis S, et al. DNA Repair (Amst). 2013 Jun 1;12(6):394-402. doi: 10.1016/j.dnarep.2013.02.003. Epub 2013 Apr 6. DNA Repair (Amst). 2013. PMID: 23570906
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Bajrami I, et al. Among authors: miller re. Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15. Cancer Res. 2014. PMID: 24240700 Free PMC article.
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ. Holme H, et al. Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Sci Rep. 2018. PMID: 30006631 Free PMC article.
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Lord R, Rauniyar J, Morris T, Condon O, Jones R, Miller R, Hall M, Lofts F, Glasspool RM, Hudson E. Lord R, et al. Int J Gynecol Cancer. 2020 Jul;30(7):1026-1033. doi: 10.1136/ijgc-2019-000973. Epub 2020 Apr 21. Int J Gynecol Cancer. 2020. PMID: 32321768
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Yap TA, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Rodrigues DN, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova S, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Yap TA, et al. Cancer Discov. 2020 Oct;10(10):1528-1543. doi: 10.1158/2159-8290.CD-20-0163. Epub 2020 Jun 12. Cancer Discov. 2020. PMID: 32532747 Free PMC article. Clinical Trial.
720 results